Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
2.

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.

Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A.

Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22.

3.

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.

Su Y, Wei W, Robert L, Xue M, Tsoi J, Garcia-Diaz A, Homet Moreno B, Kim J, Ng RH, Lee JW, Koya RC, Comin-Anduix B, Graeber TG, Ribas A, Heath JR.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13679-13684. doi: 10.1073/pnas.1712064115. Epub 2017 Dec 11.

4.

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.

Homet Moreno B, Mok S, Comin-Anduix B, Hu-Lieskovan S, Ribas A.

Oncoimmunology. 2015 Aug 17;5(7):e1052212. doi: 10.1080/2162402X.2015.1052212. eCollection 2016 Jul.

5.

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.

Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A.

Cancer Immunol Res. 2016 Oct;4(10):845-857. Epub 2016 Sep 2.

6.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A.

N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.

7.

Excluding T Cells: Is β-Catenin the Full Story?

Hu-Lieskovan S, Homet Moreno B, Ribas A.

Cancer Cell. 2015 Jun 8;27(6):749-50. doi: 10.1016/j.ccell.2015.05.014.

8.

Anti-PD-1 therapy in melanoma.

Homet Moreno B, Parisi G, Robert L, Ribas A.

Semin Oncol. 2015 Jun;42(3):466-73. doi: 10.1053/j.seminoncol.2015.02.008. Epub 2015 Feb 13. Review.

PMID:
25965365
9.

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.

Homet Moreno B, Ribas A.

Br J Cancer. 2015 Apr 28;112(9):1421-7. doi: 10.1038/bjc.2015.124. Epub 2015 Apr 9. Review.

10.

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.

Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A.

Sci Transl Med. 2015 Mar 18;7(279):279ra41. doi: 10.1126/scitranslmed.aaa4691.

11.

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.

Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A.

J Clin Oncol. 2014 Jul 20;32(21):2248-54. doi: 10.1200/JCO.2013.52.1377. Epub 2014 Jun 23. Review.

12.

Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Homet Moreno B, Garralda Cabanas E, Hitt R.

Clin Transl Oncol. 2010 Jul;12(7):468-72. doi: 10.1007/s12094-010-0539-z. Review.

PMID:
20615823

Supplemental Content

Loading ...
Support Center